Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Gilteritinib in Hepatic Impairment
NCT02571816Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2015
- Primary completion
- Mar 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of gilteritinib in acute myeloid leukemia (AML) (3 arms), sponsored by Astellas Pharma. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Infinity, Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration and 1 more. Started Oct 2015; status: completed.
02
Drugs
gilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02571816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02571816.